|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
101,000,000 |
Market
Cap: |
665.59(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.7528 - $16.06 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 9.5 |
Insider 3/6 Months : 10.1 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Co.'s primary product candidate, ADVM-022, is a single, in-office intravitreal (IVT) injection gene therapy product. ADVM-022 is being developed for the treatment of patients with wet age-related macular degeneration who are responsive to anti-vascular endothelial growth factor therapy. Co.'s second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy via a single IVT injection.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
230,000 |
230,000 |
330,000 |
Total Buy Value |
$0 |
$310,500 |
$310,500 |
$455,990 |
Total People Bought |
0 |
2 |
2 |
3 |
Total Buy Transactions |
0 |
2 |
2 |
3 |
Total Shares Sold |
0 |
0 |
6,201 |
140,082 |
Total Sell Value |
$0 |
$0 |
$9,429 |
$134,803 |
Total People Sold |
0 |
0 |
1 |
5 |
Total Sell Transactions |
0 |
0 |
1 |
9 |
End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Wachter Paul |
Director |
|
2015-06-01 |
4 |
AS |
$36.11 |
$43,191 |
I/I |
(1,192) |
39,545 |
|
- |
|
Schwartz Steven Daniel |
Director |
|
2015-06-01 |
4 |
AS |
$36.11 |
$625,043 |
D/D |
(17,250) |
384,806 |
|
- |
|
Guerin John Patrick Et Al |
Director |
|
2015-05-28 |
4 |
S |
$208.00 |
$208 |
I/I |
(1) |
150,699 |
|
- |
|
Gasmi Mehdi |
VP, Pharmaceutical Development |
|
2015-05-28 |
4 |
AS |
$38.02 |
$19,009 |
D/D |
(500) |
7,000 |
|
- |
|
Gasmi Mehdi |
VP, Pharmaceutical Development |
|
2015-05-28 |
4 |
OE |
$2.75 |
$1,375 |
D/D |
500 |
7,500 |
|
- |
|
Guerin John Patrick Et Al |
Director |
|
2015-05-27 |
4 |
S |
$206.00 |
$248,230 |
I/I |
(1,205) |
150,700 |
|
- |
|
Wachter Paul |
Director |
|
2015-05-26 |
4 |
AS |
$36.52 |
$44,037 |
I/I |
(1,192) |
40,737 |
|
- |
|
Schwartz Steven Daniel |
Director |
|
2015-05-22 |
4 |
AS |
$38.16 |
$647,687 |
D/D |
(16,875) |
402,056 |
|
- |
|
Gasmi Mehdi |
VP, Pharmaceutical Development |
|
2015-05-21 |
4 |
AS |
$38.87 |
$19,435 |
D/D |
(500) |
7,000 |
|
- |
|
Gasmi Mehdi |
VP, Pharmaceutical Development |
|
2015-05-21 |
4 |
OE |
$2.75 |
$1,375 |
D/D |
500 |
7,500 |
|
- |
|
Blumenkranz Mark S. |
Director |
|
2015-05-19 |
4 |
AS |
$36.91 |
$110,734 |
I/I |
(3,000) |
10,531 |
|
- |
|
Wachter Paul |
Director |
|
2015-05-18 |
4 |
AS |
$35.31 |
$42,086 |
I/I |
(1,192) |
41,929 |
|
- |
|
Blumenkranz Mark S. |
Director |
|
2015-05-15 |
4 |
AS |
$35.36 |
$798,553 |
D/D |
(22,500) |
552,989 |
|
- |
|
Gasmi Mehdi |
VP, Pharmaceutical Development |
|
2015-05-14 |
4 |
AS |
$35.31 |
$17,656 |
D/D |
(500) |
7,000 |
|
- |
|
Gasmi Mehdi |
VP, Pharmaceutical Development |
|
2015-05-14 |
4 |
OE |
$2.75 |
$1,375 |
D/D |
500 |
7,500 |
|
- |
|
Blumenkranz Mark S. |
Director |
|
2015-05-13 |
4 |
AS |
$34.94 |
$24,984 |
D/D |
(715) |
575,489 |
|
- |
|
Bain Linda |
Chief Financial Officer |
|
2015-05-13 |
4 |
AS |
$34.94 |
$9,959 |
D/D |
(285) |
9,000 |
|
- |
|
Bain Linda |
Chief Financial Officer |
|
2015-05-13 |
4 |
OE |
$3.15 |
$898 |
D/D |
285 |
9,285 |
|
- |
|
Blumenkranz Mark S. |
Director |
|
2015-05-11 |
4 |
AS |
$34.91 |
$62,323 |
D/D |
(1,785) |
576,204 |
|
- |
|
Wachter Paul |
Director |
|
2015-05-11 |
4 |
AS |
$32.80 |
$39,792 |
I/I |
(1,192) |
43,121 |
|
- |
|
Bain Linda |
Chief Financial Officer |
|
2015-05-11 |
4 |
AS |
$34.91 |
$24,964 |
D/D |
(715) |
9,000 |
|
- |
|
Bain Linda |
Chief Financial Officer |
|
2015-05-11 |
4 |
OE |
$3.15 |
$2,252 |
D/D |
715 |
9,715 |
|
- |
|
Schwartz Steven Daniel |
Director |
|
2015-05-08 |
4 |
AS |
$33.05 |
$570,092 |
D/D |
(17,250) |
418,931 |
|
- |
|
Gasmi Mehdi |
VP, Pharmaceutical Development |
|
2015-05-07 |
4 |
AS |
$33.28 |
$16,638 |
D/D |
(500) |
7,000 |
|
- |
|
Gasmi Mehdi |
VP, Pharmaceutical Development |
|
2015-05-07 |
4 |
OE |
$2.75 |
$1,375 |
D/D |
500 |
7,500 |
|
- |
|
266 Records found
|
|
Page 8 of 11 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|